北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 介入治疗科  > 期刊论文
学科主题: 临床医学
题名:
Low-dose, short-interval target vessel regional chemotherapy through the hepatic artery combined with transarterial embolization in gastric cancer patients with liver metastases after failure of first-line or second-line chemotherapy: a preliminary analysis
作者: Chen, Hui; Liu, Peng; Xu, Hai-Feng; Wang, Xiao-Dong; Zhu, Xu; Gao, Song; Cao, Guang; Zhu, Lin-Zhong; Guo, Jian-Hai
关键词: gastric cancer ; hepatic artery ; hepatic metastasis ; target vessel regional chemotherapy ; transarterial embolization
刊名: ANTI-CANCER DRUGS
发表日期: 2014
DOI: 10.1097/CAD.0000000000000027
卷: 25, 期:1, 页:92-100
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology ; Pharmacology & Pharmacy
研究领域[WOS]: Oncology ; Pharmacology & Pharmacy
关键词[WOS]: RANDOMIZED PHASE-II ; COLORECTAL-CANCER ; EUROPEAN-ORGANIZATION ; SURGICAL RESECTION ; COOPERATIVE GROUP ; FOLINIC ACID ; MITOMYCIN-C ; CISPLATIN ; FLUOROURACIL ; OXALIPLATIN
英文摘要:

The objective of this study is to evaluate the efficacy and safety of combining low-dose, short-interval target vessel regional chemotherapy delivered through the hepatic artery (TVRCLDSI) with transarterial embolization (TAE) in advanced gastric cancer (AGC) patients with liver metastases after failure of first-line or second-line chemotherapy. All AGC patients with hepatic metastases had an indwelling arterial catheter placed in the hepatic artery and hepatic metastases were embolized with ultrafluid lipiodol, followed by two to three TVRCLDSI treatments in one cycle. After 3 weeks, the efficacy of TVRCLDSI treatment was evaluated using computed tomography (CT) or MRI scans before starting the next cycle. Follow-up assessments were performed every 2 months. The patients received a median of 7 (2-33) TVRCLDSI treatments together with TAE. All 22 AGC patients received a total of 191 TVRCLDSI treatments, which included 80.1% FOLFOX, 11.0% FOLFIRI, and 8.9% DC treatments. The median time-to-progression was 5.97 months; the median survival time was 11.6 months; and the 1-year and 2-year survival rates were 45.5 and 9.1%, respectively. The median overall survival from the diagnosis of liver metastasis (mOS(LM)) was 19.3 months. The most common side effects were grade I-II of abdominal pain, nausea, and vomiting. Combining TAE and TVRCLDSI administration through the hepatic artery for AGC patients with liver metastases resulted in decreased overall dose of chemotherapy, alleviation of side effects, and increased QOL of patient. This approach can be used as salvage therapy for AGC patients with predominant liver metastases after failure of intravenous chemotherapy. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.

语种: 英语
项目资助者: Sanofi-Aventis Company
WOS记录号: WOS:000327786900011
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/58847
Appears in Collections:北京大学临床肿瘤学院_介入治疗科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Canc Hosp, Dept Intervent Therapy, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China

Recommended Citation:
Chen, Hui,Liu, Peng,Xu, Hai-Feng,et al. Low-dose, short-interval target vessel regional chemotherapy through the hepatic artery combined with transarterial embolization in gastric cancer patients with liver metastases after failure of first-line or second-line chemotherapy: a preliminary analysis[J]. ANTI-CANCER DRUGS,2014,25(1):92-100.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Chen, Hui]'s Articles
[Liu, Peng]'s Articles
[Xu, Hai-Feng]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Chen, Hui]‘s Articles
[Liu, Peng]‘s Articles
[Xu, Hai-Feng]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace